Anchors immediately

Instant stability

Multiple cut-outs allow the fiducial marker to fold

The fiducial marker is passive and will form different shapes depending on implantation technique. The unique design of Gold Anchor is protected by several international patents.

  • Line shaped markers minimize CT/CBCT artifacts and dose perturbation (in particle therapy).
  • Ball shaped (folded) markers provide enhanced MRI visibility and are suitable for systems with automatic marker detection.

Benefits

  • Anchors directly
  • Save lead time and travel

Anchors directly

Gold Anchor gets a great tissue attachment when the marker folds. The ball shaped marker becomes thicker than the needle tract and that prevents the marker from migrating in the needle tract when the needle is withdrawn. Other fiducial markers are smaller than the needle and can therefore migrate in the needle tract.
Even as a line shaped marker the cut-outs in the Gold Anchor marker ensure a strong tissue attachment. The flexibility of the marker also allows it to absorb tissue deformation effectively.

Save lead time and travel

With Gold Anchor there is no need wait the usual 7-21 day before dose planning. The thin Gold Anchor needle, that causes minimal bleeding and swelling, in combination with the strong tissue attachment of the marker, makes it possible to proceed with CT and/or MR for dose plan on the same day as implantation.
Note: Most centers that use traditional markers send their patient home for 7-21 days after implantation to allow the traditional markers to “settle in”, i.e. to allow the potential bleeding and swelling subside to reduce the risk that the traditional markers migrate in the tissue.

“Since incorporating The Gold Anchor into my practice, we have been able to treat patients with an increased level of efficiency, safety, and accuracy. Its thin needles allow for a more tolerable fiducial marker, which has led to significantly lower infection rates post placement.

The unique design minimizes migration after placement, which leads to consistent CT imaging as treatment continues. All of this allows for quick and accurate care.”

Scot Ackerman, M.D., FACR

Radiation Oncologist, Medical Director, Ackerman Cancer Center